Style | Citing Format |
---|---|
MLA | Babakhani D, et al.. "Renal Cell Carcinoma Derived Exosome As Natural Nanoparticles Inhibits T Cell Proliferation and Induces Their Apoptosis." Nanomedicine Research Journal, vol. 8, no. 3, 2023, pp. 277-282. |
APA | Babakhani D, Daneshdoust D, Baharvand A, Mivefroshan A, Raeisi I, Zuhair Talib Alnaqeeb B, Tavakoli F (2023). Renal Cell Carcinoma Derived Exosome As Natural Nanoparticles Inhibits T Cell Proliferation and Induces Their Apoptosis. Nanomedicine Research Journal, 8(3), 277-282. |
Chicago | Babakhani D, Daneshdoust D, Baharvand A, Mivefroshan A, Raeisi I, Zuhair Talib Alnaqeeb B, Tavakoli F. "Renal Cell Carcinoma Derived Exosome As Natural Nanoparticles Inhibits T Cell Proliferation and Induces Their Apoptosis." Nanomedicine Research Journal 8, no. 3 (2023): 277-282. |
Harvard | Babakhani D et al. (2023) 'Renal Cell Carcinoma Derived Exosome As Natural Nanoparticles Inhibits T Cell Proliferation and Induces Their Apoptosis', Nanomedicine Research Journal, 8(3), pp. 277-282. |
Vancouver | Babakhani D, Daneshdoust D, Baharvand A, Mivefroshan A, Raeisi I, Zuhair Talib Alnaqeeb B, et al.. Renal Cell Carcinoma Derived Exosome As Natural Nanoparticles Inhibits T Cell Proliferation and Induces Their Apoptosis. Nanomedicine Research Journal. 2023;8(3):277-282. |
BibTex | @article{ author = {Babakhani D and Daneshdoust D and Baharvand A and Mivefroshan A and Raeisi I and Zuhair Talib Alnaqeeb B and Tavakoli F}, title = {Renal Cell Carcinoma Derived Exosome As Natural Nanoparticles Inhibits T Cell Proliferation and Induces Their Apoptosis}, journal = {Nanomedicine Research Journal}, volume = {8}, number = {3}, pages = {277-282}, year = {2023} } |
RIS | TY - JOUR AU - Babakhani D AU - Daneshdoust D AU - Baharvand A AU - Mivefroshan A AU - Raeisi I AU - Zuhair Talib Alnaqeeb B AU - Tavakoli F TI - Renal Cell Carcinoma Derived Exosome As Natural Nanoparticles Inhibits T Cell Proliferation and Induces Their Apoptosis JO - Nanomedicine Research Journal VL - 8 IS - 3 SP - 277 EP - 282 PY - 2023 ER - |